WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today the company will host an AI panel during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The panel, titled "AI in Biopharma: Next Frontier of Medical Innovation," will explore the transformative potential of artificial intelligence in the biopharma industry. Panelists will include Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare of Microsoft (Nasdaq: MSFT ), Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, and Dr. Sean Tunis, Principal of Rubix Health.
The discussion will highlight how AI-driven technologies can revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster quicker innovation, and significantly reduce operating costs. Attendees can expect insights into how Tevogen.AI is leveraging advanced AI capabilities to advance precision T cell therapies for infectious diseases, cancers, and neurological disorders.
kAmtG6?E s6E2:=Dk^Am kAms2E6ik^AmkAm|@?52J[ y2?F2CJ 'b[ a_adk^AmkAm{@42E:@?ik^AmkAm|2C:?6DV |6>@C:2= r=F3 U2>Aj w@E6=[ e_h $FEE6C $E[ $2? uC2?4:D4@[ rp hc'_ak^AmkAm%:>6 W!$%Xik^AmkAmai__ !| - aib_ !| - px :? q:@A92C>2i }6IE uC@?E:6C @7 |65:42= x??@G2E:@?k^AmkAmaib_ !| - bi'd !| - p7E6C?@@? r@7766 qC62<k^AmkAmbi'd !| - ci__ !| - !:@?66C:?8 E96 t4@?@>:4D @7 w62=E9i q2=2?4:?8 p446DD 2?5 ~FE4@>6Dk^Am kAmci__ !| - ei__ !| - #646AE:@? 2?5 r@4<E2:=Dk^AmkAmu@C :?BF:C:6D C682C5:?8 255:E:@?2= 6G6?E 56E2:=D[ A=62D6 4@?E24E k2 9C67lQ>2:=E@i4@>>F?:42E:@?DoE6G@86?]4@>Qm4@>>F?:42E:@?DoE6G@86?]4@>k^2m]k^AmkAmp3@FE %6G@86? q:@k^AmkAm%6G@86? :D 2 4=:?:42=\DE286 DA64:2=EJ :>>F?@E96C2AJ 4@>A2?J 92C?6DD:?8 @?6 @7 ?2EFC6'D >@DE A@H6C7F= :>>F?@=@8:42= H62A@?D[ rsgZ 4JE@E@I:4 % =J>A9@4JE6D[ E@ 56G6=@A @77\E96\D96=7[ 86?6E:42==J F?>@5:7:65 AC64:D:@? % 46== E96C2A:6D 7@C E96 EC62E>6?E @7 :?764E:@FD 5:D62D6D[ 42?46CD[ 2?5 ?6FC@=@8:42= 5:D@C56CD[ 2:>:?8 E@ 255C6DD E96 D:8?:7:42?E F?>6E ?665D @7 =2C86 A2E:6?E A@AF=2E:@?D] %6G@86? {6256CD9:A 36=:6G6D E92E DFDE2:?23:=:EJ 2?5 4@>>6C4:2= DF446DD :? E96 4FCC6?E 6C2 @7 962=E942C6 C6=J @? 6?DFC:?8 A2E:6?E 2446DD:3:=:EJ E9C@F89 25G2?465 D4:6?46 2?5 :??@G2E:G6 3FD:?6DD >@56=D] %6G@86? 92D C6A@CE65 A@D:E:G6 D276EJ 52E2 7C@> :ED AC@@7\@7\4@?46AE 4=:?:42= EC:2=[ 2?5 :ED <6J :?E6==64EF2= AC@A6CEJ 2DD6ED 2C6 H9@==J @H?65 3J E96 4@>A2?J[ ?@E DF3;64E E@ 2?J E9:C5\A2CEJ =:46?D:?8 28C66>6?ED] %96D6 2DD6ED :?4=F56 E9C66 8C2?E65 A2E6?ED[ ?:?6 A6?5:?8 &$ 2?5 EH6=G6 6I\&$ A6?5:?8 A2E6?ED[ EH@ @7 H9:49 2C6 C6=2E65 E@ 2CE:7:4:2= :?E6==:86?46]k^AmkAm%6G@86? :D 5C:G6? 3J 2 E62> @7 9:89=J 6IA6C:6?465 :?5FDECJ =6256CD 2?5 5:DE:?8F:D965 D4:6?E:DED H:E9 5CF8 56G6=@A>6?E 2?5 8=@32= AC@5F4E =2F?49 6IA6C:6?46] %6G@86?'D =6256CD9:A 36=:6G6D E92E 2446DD:3=6 A6CD@?2=:K65 E96C2A6FE:4D 2C6 E96 ?6IE 7C@?E:6C @7 >65:4:?6[ 2?5 E92E 5:DCFAE:G6 3FD:?6DD >@56=D 2C6 C6BF:C65 E@ DFDE2:? >65:42= :??@G2E:@?]k^AmkAmr@?E24EDk^AmkAm%6G@86? q:@ r@>>F?:42E:@?Dk^AmkAm%i ' gff %t'~vt}[ tIE f_'k^AmkAmk2 9C67lQ>2:=E@ir@>>F?:42E:@?Do%6G@86?]4@>Qmr@>>F?:42E:@?Do%6G@86?]4@>k^2mk^AmkAmk^AmkAmk^Am